Rein Therapeutics Q2 net loss narrows on lower R&D spending

Rein Therapeutics

14/08/2026 11:54

Overview
US biopharma firm's Q2 net loss narrowed year-over-year
Company completed $57.5 mln public offering to fund Phase 2 trial for LTI-03 in IPF
Phase 2 RENEW trial enrollment for LTI-03 in IPF surpassed 25% and is ahead of schedule

Outlook
Company expects to report interim data from Phase 2 RENEW trial in H2 2026
Rein expects current cash to fund operations into Q1 2028

Result Drivers
LOWER R&D SPENDING - Co said research and development expenses fell due to reduced direct research and development services costs
REDUCED G&A EXPENSES - Co said general and administrative expenses declined mainly due to decreased employee-related expenses, including lower stock-based compensation, and reduced facilities and other expenses

Company press release: ID:nGNX72RhPt

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
Beat
$0.10
$0.17 (2 Analysts)
Q2 Net Loss
Beat
$6.38 mln
$7.29 mln (2 Analysts)
Q2 Income From Operations
Beat
-$6.08 mln
-$7.04 mln (2 Analysts)
Q2 Loss Per Basic Share
 
$0.10
 
Q2 Operating Expenses
 
$6.08 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Rein Therapeutics Inc is $6.00, about 661.9% above its August 13 closing price of $0.79

Reuters Recommended Reads
Aug 11 - Pliant Therapeutics Q2 net loss narrows on operating expenses decline, reduced headcount
Aug 11 - UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Aug 13 - Artelo Biosciences Q2 net loss narrows as R&D expenses fall

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)